Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | THRA | P10827 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12440969 | 0.91 | MAPT (0.56) | MAPTL3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL12833107 | 0.90 | THRA (0.57) | MAPTL3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL11586422 | 0.86 | KMT2A (0.46) | MAPTL3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL12440994 | 0.82 | MAPT (0.51) | MAPTL3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL13144437 | 0.82 | THRA (0.46) | MAPTL3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL16330286 | 0.82 | THRA (0.50) | MAPTL3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL13429866 | 0.82 | THRA (0.46) | MAPTL3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL13044013 | 0.81 | MAPT (0.46) | MAPTL3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL13044016 | 0.80 | MAPT (0.48) | MAPTL3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL3315111 | 0.80 | THRA (0.48) | MAPTL3MBTL1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9318706-B2 | Laminated structure, method for producing same, and electronic element comprising same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-04-19 | — | — | US | disclosed |
| US-20110177312-A1 | LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110177312-A1 | LAMINATED STRUCTURE, METHOD FOR PRODUCING SAME, AND ELECTRONIC ELEMENT COMPRISING SAME | EPCAM, ITGA1, ITGB1 | MAPT 456/4885L3MBTL1 4308/4885KDM4E 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.